Author

N. R. Lemoine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. Zhang· 2 shared J. Dong· 2 shared L. Zhang· 2 shared N. Zhang· 2 shared W. Liu· 2 shared X. Liu· 2 shared Y. Wang· 2 shared Z. Cheng· 2 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

D. Zhang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A novel viral protein translation mechanism reveals mitochondria as a target for antiviral drug development

Z. Cheng, D. Zhang, J. Chen, Y. Wu, X. Liu, L. Si, Z. Zhang, N. Zhang, Z. Zhang, W. Liu, H. Liu, L. Zhang, L. Song, L. S. C. Dunmall, J. Dong, , Y. Wang

This study identifies a viral protein translation mechanism involving mitochondrial machinery and highlights mitochondria as a target for antiviral drug development.

bioRxiv · Oct 19, 2020 · PreprintMicrobiology

An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2

z. Cheng, D. Zhang, X. Liu, J. Miao, J. wang, H. Guo, W. Yan, Z. Zhang, S. Lu, N. Zhang, J. Wang, Z. Zhang, W. Liu, Y. Zhang, L. Zhang, , Y. Wang

This study develops a cell-based chimeric vaccine against SARS-CoV-2 that induces strong T cell immunity and neutralizing antibodies without toxicity.

bioRxiv · Aug 19, 2020 · PreprintImmunology

Dysregulation of splicing-related proteins in prostate cancer is controlled by FOXA1

J. G. Foster, R. Arkell, M. Del Giudice, C. Anene, A. Lauria, J. D. G. Kelly, N. R. Lemoine, S. Oliviero, M. Cereda, P. Rajan

This study identifies FOXA1 as a key regulator of splicing-related proteins in prostate cancer, linking its dysregulation to poor patient outcomes and suggesting therapeutic targeting of splicing pathways.

bioRxiv · Dec 31, 2018 · PreprintCancer Biology